Pfizer Inc. (NYSE:PFE) Shares Bought by Semmax Financial Advisors Inc.

Semmax Financial Advisors Inc. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 111.5% during the 2nd quarter, HoldingsChannel reports. The firm owned 60,051 shares of the biopharmaceutical company’s stock after buying an additional 31,662 shares during the period. Pfizer comprises approximately 1.7% of Semmax Financial Advisors Inc.’s holdings, making the stock its 16th biggest position. Semmax Financial Advisors Inc.’s holdings in Pfizer were worth $2,601,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Weybosset Research & Management LLC boosted its position in shares of Pfizer by 2.0% during the 2nd quarter. Weybosset Research & Management LLC now owns 12,847 shares of the biopharmaceutical company’s stock valued at $557,000 after acquiring an additional 250 shares during the last quarter. Congress Asset Management Co. MA lifted its position in Pfizer by 2.0% in the fourth quarter. Congress Asset Management Co. MA now owns 13,235 shares of the biopharmaceutical company’s stock valued at $578,000 after buying an additional 254 shares during the last quarter. D.B. Root & Company LLC lifted its position in Pfizer by 0.7% in the fourth quarter. D.B. Root & Company LLC now owns 36,078 shares of the biopharmaceutical company’s stock valued at $1,575,000 after buying an additional 255 shares during the last quarter. Cottage Street Advisors LLC lifted its position in Pfizer by 4.0% in the fourth quarter. Cottage Street Advisors LLC now owns 6,677 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 255 shares during the last quarter. Finally, Financial Gravity Wealth Inc. lifted its position in Pfizer by 33.2% in the second quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 257 shares during the last quarter. 71.58% of the stock is currently owned by institutional investors.

NYSE:PFE traded down $0.74 on Friday, reaching $34.34. 20,323,181 shares of the company’s stock were exchanged, compared to its average volume of 35,302,192. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $194.03 billion, a price-to-earnings ratio of 11.45, a price-to-earnings-growth ratio of 2.80 and a beta of 0.63. The business has a fifty day moving average of $39.60 and a 200-day moving average of $41.43. Pfizer Inc. has a 52-week low of $33.97 and a 52-week high of $46.47.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.05. The company had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The business’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.77 earnings per share. As a group, equities analysts anticipate that Pfizer Inc. will post 2.8 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd will be paid a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, August 1st. This represents a $1.44 dividend on an annualized basis and a yield of 4.19%. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

In related news, insider Alexander R. Mackenzie sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the sale, the insider now directly owns 80,094 shares in the company, valued at $3,524,136. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Frank A. Damelio sold 153,184 shares of the company’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the sale, the executive vice president now owns 489,647 shares in the company, valued at $21,588,536.23. The disclosure for this sale can be found here. 0.09% of the stock is owned by corporate insiders.

A number of research analysts have commented on PFE shares. Goldman Sachs Group reaffirmed a “buy” rating and issued a $49.00 target price on shares of Pfizer in a research report on Monday, June 17th. UBS Group reaffirmed a “neutral” rating and issued a $43.00 target price on shares of Pfizer in a research report on Monday, August 5th. Credit Suisse Group reaffirmed a “neutral” rating on shares of Pfizer in a research report on Monday, August 12th. Barclays reaffirmed a “hold” rating and issued a $41.00 target price on shares of Pfizer in a research report on Thursday, May 9th. Finally, Morgan Stanley cut shares of Pfizer from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $48.00 to $40.00 in a research report on Tuesday, July 30th. Fourteen investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $46.67.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: What are benefits of a growth and income fund?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.